Skip to main content
ERNA
NASDAQ Life Sciences

Ernexa Q3 2026: $5.6M Cash, Going-Concern Warning, $12.5M Nine-Month Loss

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.88
Mkt Cap
$3.069M
52W Low
$1.74
52W High
$46.113
52W Position info
8.0% above low
Off High info
96% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

ERNA is trading near its 52-week low of $1.74 (8.0% above the low) on light trading volume (0.2× avg).

Summary

Ernexa posted a $2.9 million Q3 net loss and held $5.6 million of cash, explicitly flagging that it cannot fund the next twelve months without ATM sales and new financing, while remaining under a Nasdaq panel monitor through May 2027.


Key Events · Earnings and Guidance · ERNA

  • Q3 Loss and Nine-Month Burn

    Net loss of $2.9 million for the three months and $12.5 million for the nine months ended September 30, 2026, with $9.6 million of cash used in operating activities.

  • Going-Concern Shortfall Disclosed

    Cash of $5.6 million at September 30, 2026 is less than the amount needed for the next twelve months; management expects ATM access to cover a significant portion of the gap and is pursuing other financing.

  • ATM Is the Funding Backstop

    Net proceeds of $3.7 million under the $9.2 million ATM as of September 30, 2026, plus 43,700 shares for $0.1 million sold on October 6, 2026, leaving roughly $5.3 million available.

  • Goodwill Fully Impaired

    A $2.0 million non-cash goodwill impairment was recorded in the nine months ended September 30, 2026, leaving no goodwill on the balance sheet.


Analysis · ERNA · Life Sciences

Cash of $5.6 million at September 30, 2026 stands against a $12.5 million nine-month net loss and $9.6 million of operating cash burn, and management states plainly that this is less than needed to fund the next twelve months. The plan leans on roughly $5.3 million of remaining ATM capacity plus unspecified additional financings, which makes further share sales the base case rather than a contingency. Operationally the quarter was quiet, with a $2.9 million net loss and no revenue, but the nine-month period carried a $2.0 million non-cash goodwill impairment that wiped the remaining goodwill off the balance sheet. Layered on top is the Nasdaq overhang: the panel's jurisdiction ended September 14, 2026, yet a mandatory monitor runs through May 5, 2027, and any renewed bid-price deficiency triggers an immediate delisting determination. For a company this small, cash runway and listing status are the thesis.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ERNA was trading at $1.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1M. The 52-week trading range was $1.74 to $46.11. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ERNA - Latest Insights

ERNA
Sep 30, 2026, 8:32 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.52
Real-time Price: $1.63 info
Change: -$1.89 (-54%) info
Market Cap: $2.302M info
ERNA
Sep 15, 2026, 8:42 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.54
Real-time Price: $1.63 info
Change: -$1.91 (-54%) info
Market Cap: $2.302M info
ERNA
Aug 06, 2026, 5:31 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.57
Real-time Price: $1.63 info
Change: -$2.94 (-64%) info
Market Cap: $2.302M info
ERNA
Jul 15, 2026, 7:50 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $11.04
Real-time Price: $1.63 info
Change: -$9.41 (-85%) info
Market Cap: $2.302M info
ERNA
Jul 02, 2026, 4:40 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.20
Real-time Price: $1.63 info
Change: -$4.57 (-74%) info
Market Cap: $2.302M info